Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Translational Stroke Research
Published in: Translational Stroke Research 4/2017

01-08-2017 | Opinion Paper

The High Cost of Stroke and Stroke Cytoprotection Research

Authors: Paul A. Lapchak, John H. Zhang

Published in: Translational Stroke Research | Issue 4/2017

Login to get access

Abstract

Acute ischemic stroke is inadequately treated in the USA and worldwide due to a lengthy history of neuroprotective drug failures in clinical trials. The majority of victims must endure life-long disabilities that not only affect their livelihood, but also have an enormous societal economic impact. The rapid development of a neuroprotective or cytoprotective compound would allow future stroke victims to receive a treatment to reduce disabilities and further promote recovery of function. This opinion article reviews in detail the enormous costs associated with developing a small molecule to treat stroke, as well as providing a timely overview of the cell-death time-course and relationship to the ischemic cascade. Distinct temporal patterns of cell-death of neurovascular unit components provide opportunities to intervene and optimize new cytoprotective strategies. However, adequate research funding is mandatory to allow stroke researchers to develop and test their novel therapeutic approach to treat stroke victims.
Literature
1.
2.
Wepfer J. Observationes anatomicae ex cadaveribus eorum quos sustulit apoplexia (cum exercitatione de eious loco affecto). Schaffussii: J C Suteri. 1658:670.
3.
Gurdjian ES, Gurdjian ES. History of occlusive cerebrovascular disease I. From Wepfer to Moniz. Arch Neurol. 1979;36(6):340–3.PubMedCrossRef
4.
Willis T. Cerebri Anatome: cui accessit nervorum descriptio et usus. London; 1664.
5.
Virchow R. Thrombose und Embolie: Gefässenzýndung und Septische Infektion, in Gesammelte Abhandlungen zur wissen schaftlichen Medicin: Frankfurt, a. M., Meidinger, Sohn und Co, 1856.
6.
Dechambre A. Dictionnaire Encyclopédique des Sciences Médicales. Paris; 1866.
7.
Bramwell B. Spontaneous meningeal haemorrhage. Edinburgh Medical Journal. 1886;32:101.
8.
Symonds CP. Spontaneous sub-arachnoid haemorrhage. Proceedings of the Royal Society of Medicine. Neurol Sect. 1924;17:39–52.
9.
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation. 2009;119(3):480–6.PubMedCrossRef
10.
Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948–54.PubMedCrossRef
11.
Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–e215.PubMedCrossRef
12.
Lapchak PA. Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr Neurol Neurosci Rep. 2002;2(1):38–43.PubMedCrossRef
13.
Lyden PD, Zivin JA. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev. 1993;5(1):1–16.PubMed
14.
Bernstein RA, Del-Signore M. Recent advances in the management of acute intracerebral hemorrhage. Curr Neurol Neurosci Rep. 2005;5(6):483–7.PubMedCrossRef
15.
16.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.PubMedCrossRef
17.
18.
Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990–2010: findings from the global burden of disease study 2010. Lancet. 2014;383(9913):245–54.PubMedPubMedCentralCrossRef
19.
Suwanwela NC, Poungvarin N. Asian stroke advisory P. Stroke burden and stroke care system in Asia. Neurol India. 2016;64(Suppl):S46–51.PubMedCrossRef
20.
Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015;372(14):1333–41.PubMedPubMedCentralCrossRef
21.
22.
23.
24.
25.
26.
27.
28.
Bendszus M, Thomalla G, Hacke W, Knauth M, Gerloff C, Bonekamp S, et al. Early termination of THRILL, a prospective study of mechanical thrombectomy in patients with acute ischemic stroke ineligible for i.V. Thrombolysis. Clin Neuroradiol. 2016; doi:10.​1007/​s00062-016-0538-8.PubMedCentral
29.
30.
31.
Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723–31.PubMedCrossRef
32.
Berkhemer OAFP, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11–20.PubMedCrossRef
33.
Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019–30.PubMedCrossRef
34.
Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11):1009–18.PubMedCrossRef
35.
Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296–306.PubMedCrossRef
36.
Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372(24):2285–95.PubMedCrossRef
37.
Rebello LC, Haussen DC, Grossberg JA, Belagaje S, Lima A, Anderson A, et al. Early endovascular treatment in intravenous tissue plasminogen activator-ineligible patients. Stroke. 2016;47(4):1131–4.PubMedCrossRef
38.
Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, et al. 2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(10):3020–35.PubMedCrossRef
39.
Xie X, Lambrinos A, Chan B, Dhalla IA, Krings T, Casaubon LK, et al. Mechanical thrombectomy in patients with acute ischemic stroke: a cost-utility analysis. CMAJ Open. 2016;4(2):E316–25.PubMedPubMedCentralCrossRef
40.
Aronsson M, Persson J, Blomstrand C, Wester P, Levin LA. Cost-effectiveness of endovascular thrombectomy in patients with acute ischemic stroke. Neurology. 2016;86(11):1053–9.PubMedCrossRef
41.
Mangla S, O'Connell K, Kumari D, Shahrzad M. Novel model of direct and indirect cost-benefit analysis of mechanical embolectomy over IV tPA for large vessel occlusions: a real-world dollar analysis based on improvements in mRS. J Neurointerv Surg. 2016; doi:10.​1136/​neurintsurg-2015-012152.PubMed
42.
Lobotesis K, Veltkamp R, Carpenter IH, Claxton LM, Saver JL, Hodgson R. Cost-effectiveness of stent-retriever thrombectomy in combination with IV t-PA compared with IV t-PA alone for acute ischemic stroke in the UK. J Med Econ. 2016;19(8):785–94.PubMedCrossRef
43.
Health Quality Ontario. Mechanical thrombectomy in patients with acute ischemic stroke: a health technology assessment. Ont Health Technol Assess Ser. 2016;16(4):1–79.
44.
Ganesalingam J, Pizzo E, Morris S, Sunderland T, Ames D, Lobotesis K. Cost-utility analysis of mechanical thrombectomy using stent retrievers in acute ischemic stroke. Stroke. 2015;46(9):2591–8.PubMedPubMedCentralCrossRef
45.
Zivin JA, Simmons J. tPA for stroke : the story of a controversial drug. New York: Oxford University Press; 2011. xiv, 191 p. p.
46.
47.
48.
Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan alteplase clinical trial (J-ACT). Stroke. 2006;37(7):1810–5.PubMedCrossRef
49.
Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695–703.PubMedCrossRef
50.
Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8(12):1095–102.PubMedCrossRef
51.
NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA stroke study group. N Engl J Med. 1995;333(24):1581–7.CrossRef
52.
Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.PubMedCrossRef
53.
Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke. 2009;40(7):2438–41.PubMedPubMedCentralCrossRef
54.
55.
Reeves MJ, Arora S, Broderick JP, Frankel M, Heinrich JP, Hickenbottom S, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke. 2005;36(6):1232–40.PubMedCrossRef
56.
Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, et al. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at get with the guidelines-stroke hospitals. Circ Cardiovasc Qual Outcomes. 2013;6(5):543–9.PubMedCrossRef
57.
Joo H, Wang G, George MG. Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18-64 years in the USA. Stroke Vasc Neurol. 2016;1(1):8–15.PubMedPubMedCentralCrossRef
58.
Arora R, Salamon E, Katz JM, Cox M, Saver JL, Bhatt DL, et al. Use and outcomes of intravenous thrombolysis for acute ischemic stroke in patients >/=90 Years of age. Stroke. 2016;47(9):2347–54.PubMedCrossRef
59.
60.
Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996;27(9):1459–66.PubMedCrossRef
61.
Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med. 2013;61(1):46–55.PubMedCrossRef
62.
Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, et al. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence. Stroke. 2014;45(10):3032–9.PubMedCrossRef
63.
Henninger N, Fisher M. Extending the time window for endovascular and pharmacological reperfusion. Transl Stroke Res. 2016;7(4):284–93.PubMedCrossRef
64.
65.
Linfante I, Cipolla MJ. Improving reperfusion therapies in the era of mechanical thrombectomy. Transl Stroke Res. 2016;7(4):294–302.PubMedCrossRef
66.
67.
Lapchak PA. Critical early Thrombolytic & Endovascular Reperfusion Therapy for Acute Ischemic Stroke Victims: a call for adjunct neuroprotection. Translational Stroke Research. 2015;6(5):345–54. doi:10.​1007/​s12975-015-0419-5(6):​345-54.
68.
Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999; 30(12):2752–8.
69.
Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490(7419):187–91.PubMedPubMedCentralCrossRef
70.
71.
Lapchak PA. Recommendations and practices to optimize stroke therapy: developing effective translational research programs. Stroke. 2013;44(3):841–3.PubMedCrossRef
72.
Crossley NA, Sena E, Goehler J, Horn J, van der Worp B, Bath PM, et al. Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke. 2008;39(3):929–34.PubMedCrossRef
73.
Hirst JA, Howick J, Aronson JK, Roberts N, Perera R, Koshiaris C, et al. The need for randomization in animal trials: an overview of systematic reviews. PLoS One. 2014;9(6):e98856.PubMedPubMedCentralCrossRef
74.
75.
Saver JL, Smith EE, Fonarow GC, Reeves MJ, Zhao X, Olson DM, et al. The "golden hour" and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset. Stroke. 2010;41(7):1431–9.PubMedPubMedCentralCrossRef
76.
Lapchak PA. Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now. Transl Stroke Res. 2013;4(6):704–9.PubMedCrossRef
77.
Desai JA, Smith EE. Prenotification and other factors involved in rapid tPA administration. Curr Atheroscler Rep. 2013;15(7):337.PubMedCrossRef
78.
Olson DM, Constable M, Britz GW, Lin CB, Zimmer LO, Schwamm LH, et al. A qualitative assessment of practices associated with shorter door-to-needle time for thrombolytic therapy in acute ischemic stroke. J Neurosci Nurs. 2011;43(6):329–36.PubMedCrossRef
79.
Fonarow GC, Smith EE, Saver JL, Reeves MJ, Hernandez AF, Peterson ED, et al. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's target: stroke initiative. Stroke. 2011;42(10):2983–9.PubMedCrossRef
80.
Mokin M, Snyder KV, Siddiqui AH, Levy EI, Hopkins LN. Recent endovascular stroke trials and their impact on stroke Systems of Care. J Am Coll Cardiol. 2016;67(22):2645–55.PubMedCrossRef
81.
Carmichael ST. The 3 Rs of stroke biology: radial, relayed, and regenerative. Neurotherapeutics. 2016;13(2):348–59.PubMedCrossRef
82.
Lapchak PA. Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules. Transl Stroke Res. 2013;4(3):328–42.PubMedCrossRef
83.
Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235–49.PubMedCrossRef
84.
Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1(4):337–41.PubMedCrossRef
85.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26.PubMedCrossRef
86.
Hellinger E, Veszelka S, Toth AE, Walter F, Kittel A, Bakk ML, et al. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur J Pharm Biopharm. 2012;82(2):340–51.PubMedCrossRef
87.
Laine R. Metabolic stability: main enzymes involved and best tools to assess it. Curr Drug Metab. 2008;9(9):921–7.PubMedCrossRef
88.
Brimecombe JC, Kirsch GE, Brown AM. Test article concentrations in the hERG assay: losses through the perfusion, solubility and stability. J Pharmacol Toxicol Methods. 2009;59(1):29–34.PubMedCrossRef
89.
Cheng CS, Alderman D, Kwash J, Dessaint J, Patel R, Lescoe MK, et al. A high-throughput HERG potassium channel function assay: an old assay with a new look. Drug Dev Ind Pharm. 2002;28(2):177–91.PubMedCrossRef
90.
Gintant G. An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther. 2011;129(2):109–19.PubMedCrossRef
91.
Goineau S, Legrand C, Froget G. Whole-cell configuration of the patch-clamp technique in the hERG channel assay to predict the ability of a compound to prolong QT interval. Curr Protoc Pharmacol. 2012; Chapter 10:Unit 10 5.
92.
Yu HB, Zou BY, Wang XL, Li M. Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay. Acta Pharmacol Sin. 2016;37(1):111–23.PubMedPubMedCentralCrossRef
93.
94.
Hedlund E, Gustafsson JA, Warner M. Cytochrome P450 in the brain: a review. Curr Drug Metab. 2001;2(3):245–63.PubMedCrossRef
95.
Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, et al. Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper. Drug Metab Dispos. 2013;41(9):1598–609.PubMedCrossRef
96.
Lapchak PA, Bombien R, Rajput PS. J-147 a Novel Hydrazide Lead Compound to Treat Neurodegeneration: CeeTox Safety and Genotoxicity Analysis. J Neurol Neurophysiol. 2013 ; 4(3).
97.
Lapchak PA, Schubert DR, Maher PA. Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke. J Neurochem. 2011;116(1):122–31.PubMedCrossRef
98.
Kirsch-Volders M, Decordier I, Elhajouji A, Plas G, Aardema MJ, Fenech M. In vitro genotoxicity testing using the micronucleus assay in cell lines, human lymphocytes and 3D human skin models. Mutagenesis. 2011;26(1):177–84.PubMedCrossRef
99.
Wiesner J, Ziemann C, Hintz M, Reichenberg A, Ortmann R, Schlitzer M, et al. FR-900098, an antimalarial development candidate that inhibits the non-mevalonate isoprenoid biosynthesis pathway, shows no evidence of acute toxicity and genotoxicity. Virulence. 2016;7(6):718–28.PubMedPubMedCentralCrossRef
100.
101.
Pellegatti M. Preclinical in vivo ADME studies in drug development: a critical review. Expert Opin Drug Metab Toxicol. 2012;8(2):161–72.PubMedCrossRef
102.
Fisher M. Recommendations for advancing development of acute stroke therapies: stroke therapy academic industry roundtable 3. Stroke. 2003;34(6):1539–46.PubMedCrossRef
103.
Fisher M, Hanley DF, Howard G, Jauch EC, Warach S. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke. 2007;38(2):245–8.PubMedCrossRef
104.
Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M, Consortium SV. Stroke therapy academic industry roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke. 2009;40(7):2594–600.PubMedPubMedCentralCrossRef
105.
Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, et al. Stroke treatment academic industry roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke. 2011;42(9):2645–50.PubMedCrossRef
106.
Ahnstedt H, McCullough LD, Cipolla MJ. The importance of considering sex differences in translational stroke research. Transl Stroke Res. 2016;7(4):261–73.PubMedCrossRef
107.
Ergul A, Hafez S, Fouda A, Fagan SC. Impact of comorbidities on acute injury and recovery in preclinical stroke research: focus on hypertension and diabetes. Transl Stroke Res. 2016;7(4):248–60.PubMedCrossRef
108.
109.
Sasase T, Ohta T, Masuyama T, Yokoi N, Kakehashi A, Shinohara M. The spontaneously diabetic torii rat: an animal model of nonobese type 2 diabetes with severe diabetic complications. J Diabetes Res. 2013;2013:976209.PubMedPubMedCentral
110.
Kemmochi Y, Fukui K, Maki M, Kimura S, Ishii Y, Sasase T, et al. Metabolic disorders and diabetic complications in spontaneously diabetic Torii Lepr (fa) rat: a new obese type 2 diabetic model. J Diabetes Res. 2013;2013:948257.PubMedPubMedCentralCrossRef
111.
Hossmann KA. The two pathophysiologies of focal brain ischemia: implications for translational stroke research. J Cereb Blood Flow Metab. 2012;32(7):1310–6.PubMedPubMedCentralCrossRef
112.
Lapchak PA. A clinically relevant rabbit embolic stroke model for acute ischemic stroke therapy development: mechanisms & targets. In: Lapchak PA, Zhang JH, editors.: Translational Stroke Research: From Target Selection to Clinical Trials, Springer, USA; 2011. Chapter 27, p. 541–84
113.
Lapchak PA. A cost-effective rabbit embolic stroke bioassay: insight into the development of acute ischemic stroke therapy. Transl Stroke Res. 2015;6(2):99–103.PubMedPubMedCentralCrossRef
114.
Turner R, Jickling G. Sharp, F are underlying assumptions of current animal models of human stroke correct: from STAIRS to high hurdles? Translational Stroke Research. 2011;2(2):138–43.PubMedPubMedCentralCrossRef
115.
Kent TA, Mandava P. Embracing biological and methodological variance in a new approach to pre-clinical stroke testing. Transl Stroke Res. 2016;7(4):274–83.PubMedCrossRef
116.
Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000;31(12):3034–40.PubMedCrossRef
117.
Liu DZ, Sharp FR. Excitatory and Mitogenic signaling in cell death, blood-brain barrier breakdown, and BBB repair after intracerebral hemorrhage. Transl Stroke Res. 2012;3(Suppl 1):62–9.PubMedCrossRef
118.
Turner RJ, Sharp FR. Implications of MMP9 for blood brain barrier disruption and hemorrhagic transformation following ischemic stroke. Front Cell Neurosci. 2016;10:56.PubMedPubMedCentralCrossRef
119.
Kassner A, Merali Z. Assessment of blood-brain barrier disruption in stroke. Stroke. 2015;46(11):3310–5.PubMedCrossRef
120.
121.
Demaerschalk BM. Alteplase treatment in acute stroke: incorporating Food and Drug Administration prescribing information into existing acute stroke management guide. Curr Atheroscler Rep. 2016;18(8):53.PubMedCrossRef
122.
Benz RD. Toxicological and clinical computational analysis and the US FDA/CDER. Expert Opin Drug Metab Toxicol. 2007;3(1):109–24.PubMedCrossRef
123.
Muller PY, Milton M, Lloyd P, Sims J, Brennan FR. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr Opin Biotechnol. 2009;20(6):722–9.PubMedCrossRef
124.
125.
Lapchak PA, Araujo DM, Zivin JA. Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol. 2004;185(1):154–9.PubMedCrossRef
126.
127.
Meador V, Jordan W, Zimmermann J. Increasing throughput in lead optimization in vivo toxicity screens. Curr Opin Drug Discov Devel. 2002;5(1):72–8.PubMed
128.
Yoon M, Campbell JL, Andersen ME, Clewell HJ. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit Rev Toxicol. 2012;42(8):633–52.PubMedCrossRef
129.
Lee SR, Wang X, Tsuji K, Lo EH. Extracellular proteolytic pathophysiology in the neurovascular unit after stroke. Neurol Res. 2004;26(8):854–61.PubMedCrossRef
130.
Richardson J, Murray D, House CK, Lowenkopf T. Successful implementation of the National Institutes of Health stroke scale on a stroke/neurovascular unit. J Neurosci Nurs. 2006;38(4 Suppl):309–15.PubMedCrossRef
131.
132.
Ago T. The neurovascular unit in health and ischemic stroke. Nihon Rinsho. 2016;74(4):583–8.PubMed
133.
Cai W, Zhang K, Li P, Zhu L, Xu J, Yang B, et al. Dysfunction of the neurovascular unit in ischemic stroke and neurodegenerative diseases: An aging effect. Ageing Res Rev 2016.
134.
ElAli A. The implication of neurovascular unit signaling in controlling the subtle balance between injury and repair following ischemic stroke. Neural Regen Res. 2016;11(6):914–5.PubMedPubMedCentral
135.
136.
Hermann DM, Buga AM, Popa-Wagner A. Neurovascular remodeling in the aged ischemic brain. J Neural Transm (Vienna). 2015;122(Suppl 1):S25–33.CrossRef
137.
138.
Redzic ZB, Rabie T, Sutherland BA, Buchan AM. Differential effects of paracrine factors on the survival of cells of the neurovascular unit during oxygen glucose deprivation. Int J Stroke. 2015;10(3):407–14.PubMedCrossRef
139.
Barakat R, Redzic Z. Differential cytokine expression by brain microglia/macrophages in primary culture after oxygen glucose deprivation and their protective effects on astrocytes during anoxia. Fluids Barriers CNS. 2015;12:6.PubMedPubMedCentralCrossRef
140.
Dirnagl U. Pathobiology of injury after stroke: the neurovascular unit and beyond. Ann N Y Acad Sci. 2012;1268:21–5.PubMedCrossRef
141.
Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22(9):391–7.PubMedCrossRef
142.
143.
144.
Jolkkonen J, Kwakkel G. Translational hurdles in stroke recovery studies. Transl Stroke Res. 2016;7(4):331–42.PubMedCrossRef
145.
146.
Commercial sources were utilized to estimate assay costs. Sources include Cedars-Sinai Medical Center Department of Comparative Medicine, Pharmaron Inc, Absorption Systems Inc, Ricera inc., Cyprotex Inc, and Oxygen BioResearch PVT Ltd.
Metadata
Title
The High Cost of Stroke and Stroke Cytoprotection Research
Authors
Paul A. Lapchak
John H. Zhang
Publication date
01-08-2017
Publisher
Springer US
Published in
Translational Stroke Research / Issue 4/2017
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI
https://doi.org/10.1007/s12975-016-0518-y

Other articles of this Issue 4/2017

Translational Stroke Research 4/2017 Go to the issue

Original Article

MiR-126 Affects Brain-Heart Interaction after Cerebral Ischemic Stroke

Original Article

Spontaneous Recovery of Upper Extremity Motor Impairment After Ischemic Stroke: Implications for Stem Cell-Based Therapeutic Approaches

Methods Paper

Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients

Original Article

Simvastatin Promotes Hematoma Absorption and Reduces Hydrocephalus Following Intraventricular Hemorrhage in Part by Upregulating CD36

Short Communication

Task-Specific Motor Rehabilitation Therapy After Stroke Improves Performance in a Different Motor Task: Translational Evidence

Original Article

Sodium Tanshinone IIA Sulfonate Enhances Effectiveness Rt-PA Treatment in Acute Ischemic Stroke Patients Associated with Ameliorating Blood-Brain Barrier Damage